Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Recommendation of “Moderate Buy” from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $30.2727.

Several equities research analysts have commented on the stock. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Citizens Jmp reiterated a “market outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Finally, HC Wainwright increased their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st.

Insider Buying and Selling

In other news, CEO Claire Mazumdar sold 10,000 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $28.42, for a total transaction of $284,200.00. Following the completion of the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $10,292,359.84. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total value of $817,641.72. Following the completion of the transaction, the chief operating officer owned 182,177 shares in the company, valued at $5,279,489.46. The trade was a 13.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,950 shares of company stock worth $2,492,515 over the last three months. Corporate insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BCAX. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics in the fourth quarter worth about $45,000. Legal & General Group Plc increased its position in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares in the last quarter.

Bicara Therapeutics Stock Down 0.8%

BCAX stock opened at $27.73 on Friday. The company has a 50-day simple moving average of $24.42 and a 200 day simple moving average of $20.81. The company has a market capitalization of $1.82 billion, a P/E ratio of -9.97 and a beta of -0.81. Bicara Therapeutics has a fifty-two week low of $9.57 and a fifty-two week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Equities analysts anticipate that Bicara Therapeutics will post -3.42 EPS for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.